Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pituitrin in cardiac surgery patients with pulmonary hypertension
NCT05727618Suspended
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- May 2026
- Primary completion
- Dec 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, single-blind trial of pituitrin in pulmonary hypertension (PH) (2 arms), sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoint: Composite endpoint of mortality or severe postoperative complications at 30 days. Started May 2026; status: suspended.
02
Drugs
pituitrin
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT05727618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05727618.